PET scan to monitor immunotherapy in pancreatic cancer
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial uses a special PET scan (68Ga-grazytracer) to see how well immunotherapy is working for pancreatic cancer. It may help your doctor understand if your treatment is effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with pancreatic cancer
- Your doctor has recommended a combination of immunotherapy treatments
- You are between 18 and 75 years old
- Your overall health is good enough that you are expected to live more than 6 months
- You are willing to follow the study procedures and give your consent
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses a special PET scan tracer to see how it spreads in the body for people newly diagnosed with pancreatic or head and neck cancer who haven't had treatment yet. It aims to help doctors better understand and potentially treat these cancers.
This study uses a special PET scan drug (Ga-FAPI-46) to create clearer pictures of pancreatic and bile duct cancers. It may help doctors decide on the best next steps—especially before surgery—by checking tumor size and looking for spread.
This trial uses a special PET scan called 68Ga-grazytracer to see how well immunotherapy is working in people with stomach, colon, or other gastrointestinal cancers. The goal is to find out if this scan can help doctors track your response to treatment.
This trial uses a special PET scan (68Ga-grazytracer) to see how well immunotherapy is working in people with advanced liver or bile duct cancer. The goal is to find a better way to monitor treatment response.
This trial tests a new imaging method called ImmunoPET to see if it can help detect pancreatic cancer more clearly. If you have or might have pancreatic cancer, this study could help doctors understand your condition better.
This trial uses a special PET scan (68Ga-grazytracer) to find out whether growth seen on scans after immunotherapy is real cancer growth or a harmless reaction called pseudoprogression. It helps doctors decide if your treatment is working.
Hear when a new Pancreatic cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.